The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Naiyer A. Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword

(2016) Roberta Visconti et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status

(2016) Yoshiaki Murakami et al.   JOURNAL OF SURGICAL ONCOLOGY

Pancreatic cancer

(2016) Terumi Kamisawa et al.   LANCET

The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients

(2016) Mei-Chin Hsieh et al.   Cancer Medicine

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study

(2015) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

ATM and ATR as therapeutic targets in cancer

(2015) Anika Maria Weber et al.   PHARMACOLOGY & THERAPEUTICS

CBP-93872 Inhibits NBS1-Mediated ATR Activation, Abrogating Maintenance of the DNA Double-Strand Break-Specific G2 Checkpoint

(2014) T. Hirokawa et al.   CANCER RESEARCH

Cisplatin in cancer therapy: Molecular mechanisms of action

(2014) Shaloam Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

(2014) Fotios Loupakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

(2013) Yasuhide Yamada et al.   LANCET ONCOLOGY

Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?

(2012) Hidemasa Goto et al.   CANCER SCIENCE

New Insights into p53 Signaling and Cancer Cell Response to DNA Damage: Implications for Cancer Therapy

(2012) Razmik Mirzayans et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Checkpoints meet the transcription at a novel histone milestone (H3-T11)

(2011) Midori Shimada et al.   CELL CYCLE

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticancer therapy with checkpoint inhibitors: what, where and when?

(2011) Michelle D. Garrett et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer

(2010) T. Doi et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

(2010) Cynthia X. Ma et al.   TRENDS IN MOLECULAR MEDICINE

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

Chk1 Is a Histone H3 Threonine 11 Kinase that Regulates DNA Damage-Induced Transcriptional Repression

(2008) Midori Shimada et al.   CELL